Gives them a stronger hand at the negotiating table. Trius raised in January 2013 then were purchased by Cubist in July 2013. Cempra now has cash through at least 2017. Now no pressure to raise this year, and they raised while capital markets are still ok. Dilution less than 15%.
While the market for this drug probably won't be that big, (1) Cempra can say they have two antibiotics in Phase 3 development; (2) it's a "bolt on" drug, meaning Cempra won't have to hire anyone else to sell it as they will already have a solithromycin sales force. So 80% or more of the revenue generated by the drug will hit the bottom line.